Dabur Research Foundation

Fresenius Kabi Oncology Limited

Dabur Pharma Limited

Other

Anand C Burman

Rama Mukherjee

Manu Jaggi

Sudhanand Prasad

Anu T Singh

Dhiraj Khattar

Archna Mathur

Mukesh Kumar

Manoj Kumar Singh

Rajan Sharma

Sarjana Dutt

Shobhit Kumar Singh

Praveen Rajendran

Kamal K Kapoor

Deepak Prusthy

Pawan Kumar Gupta

Rajendran Praveen

Neena Gupta

Sanjoy Mullick

Honey Bala

Mukund Keshav Gurjar

Jhillu Singh Yadav

Sanjeeb Kumar Sahoo

Gautam R Desiraju

Prasanta Kumar Ghosh

Srivari Chandrasekhar

Anand Vardhan

Vivek Kumar

Amarnath Maitra

Mohammad Jamshed Ahmed Siddiqui

Manju Ray

Radhika Dilip Wakharkar

Shiv Kumar Agarwal

Manoj Kumar Pananchukunnath

Ajeet Kumar Singh

Deepti Jain

Deepak Judgelal Parshotamdas

Rama Mukharjee

Ashwini Nangia

Hanumant Bapu Rao Borate

Anuo T Singh

Sanjay Sarkhel

Sanjay Kumar Srivastava

K V V M Sairam

Tushar Kanti Chakraborty

Hemant Kumar Jajoo

Ajit Chand Kunwar

Nidhi Rani

Rinku Ahuja

Anil K Mishra

Lazar T Mathew

Dinesh Kumar

Archana Mathur

Praveen Khullar

Rajiv Kumar Shrivastava

Perundurai S Srinivasan

Soumendu Paul

Rajesh Srivastava

Satish Chandra Upadhyay

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(&#x2550;CH)CHor CH(CH); Rtogether with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; Ror Rare hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or Rand Rare combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and Ris zero when Y is O, and Ris hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells. 

Betulinic acid derivatives

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Drug comprising synthetic peptide analogs for the treatment of cancer

A stabilized pharmaceutical composition of anticancer drug and a solvent like Polyethoxylated castor oil (cremophor) also containing any other suitable solubilizer suitable for human administration like dehydrated alcohol, is disclosed. Compositions prepared using this purified polyethoxylated castor oil enhance the stability of paclitaxel in such compositions.

Stabilized formulation

A storage stable pharmaceutical composition comprising a solution of Oxaliplatin in water and a catalytic amount of a carbohydrate. A process for forming such pharmaceutical composition comprising dissolving a known amount of Oxaliplatin in water; adding an amount of carbohydrate in the range of 0.0010% to 0.05% w/v with respect to such solution; agitating the mixture to get clear solution; filtering it through a filter membrane under aseptic conditions; and filling the solution resulting into glass vials sealed with elastomeric stoppers and aluminium flip-off seals.

Stable oxaliplatin formulation

The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias.

Cyclopentenone derivatives for cancer therapy

The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing &#x3b1;, &#x3b1;-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Vasoactive intestinal peptide analogs

Anticancer peptides which incorporate furanoid sugar amino acids and compositions made using these peptides are described. Methods for synthesis of the peptides and for preparing the furanoid sugar amino acids are disclosed. The peptides and compositions made using the peptides have pharmacological applications of these peptides especially in the treatment and prevention of cancer and tumors.

Peptides comprising furanoid sugar amino acids for the treatment of cancer

The present invention encompasses novel peptides that are antagonists to bombesin and bombesin like peptides and are useful in the treatment of cancer. The invention particularly relates to the design and synthesis of the novel peptides incorporating &#x3b1;,&#x3b1;-amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Bombesin analogs for treatment of cancer

A polypeptide of the formula (I),P-L-P-L-P-L-P.

Polypeptides of covalently linked synthetic bioactive peptide analog(s) for treatment of cancer

This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.

Peptides for treatment of cancer

The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.

Method and compositions for solubilization of pentacyclic triterpenes

The present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, melanoma, glioblastoma, oral cancer and leukemias. Although not bound to any theory, the anticancer activity of carvedilol appears to be attributed to the inhibition of Epidermal Growth Factor and Platelet derived growth factor dependent proliferation of cancer cells. Further, carvedilol exerts anticancer effect by inhibition of the Protein kinase C (PKC) activity and that of the cyclooxygenase 2 enzyme. The invention also relates to the anticancer activity of the optically pure isomers S(&minus;) and R(&plus;) of carvedilol and the use of carvedilol and its isomers in pharmaceutical compositions for the treatment of cancer.

Anti-cancer activity of carvedilol and its isomers

Growing community of inventors

Ghaziabad, India

Anand C Burman